5-Year Survival Rate of Cancers With <100K Incidence (US)

Some high-level observations:

• Cancers with the highest unmet need (high incidence, low survival) are generally a graveyard of failed treatments - lack of efficacy in pancreatic or liver cancer, for example, has been driven by an inability to deliver therapeutics effectively.
• For SCLC, diagnosis often occurs in extensive-stage, and the disease is notoriously fast-moving, with the # of patients graduating to each successive treatment line falling by >50% (1L has ~22K patients, 2L has ~9K)
• Refractory patients in well managed cancers face a different challenge - the success of upfront therapies for most patients has limited investment in reserve treatments, leaving few options
• There are of course multiple ways to measure unmet need beyond survival, namely quality of life. Across most cancers, there's a lot of opportunity to improve safety profiles, patient & caregiver burden and pain management.